Therefore, ultimately, only 10 articles including 12 studies15, 18, 19, 20, 21, 22, 23, 27, 28, 29, which met the inclusion criteria, were enrolled in the study to investigate association between BIM deletion polymorphism and clinical efficacy and survival of cancer patients with kinase inhibitor therapy. This evidence concerns the gene BCL2L11 and cancer.